Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma
This study is the first to validate the GRIm Score in malignant melanoma, suggesting it is a valuable biomarker for patient selection in immunotherapy trials. The findings highlight its potential in refining treatment decisions, though further validation in larger, multicenter cohorts is required.
Authors
- Assoc
- Heves Sürmeli (ORCID: https://orcid.org/0000-0003-1604-8466)
- Uğur Özkerim (ORCID: https://orcid.org/0000-0001-8527-1392)
- seval ay
- Sila OKSUZ
- Oguzcan Kinikoglu
- Hatice Odabaş (ORCID: https://orcid.org/0000-0002-5757-4705)
- Deniz Isik
- Utku Donem Gundogdu
- Tugba Basoglu
Institutions
- Dr Lütfi Kırdar Kartal Eğitim ve Araştırma Hastanesi (TR)
- Sağlık Bilimleri Üniversitesi (TR)
Publication Details
- Journal
- Journal of Cancer Research and Clinical Oncology
- Published
- 2026-01-08
- DOI
- https://doi.org/10.1007/s00432-025-06411-7
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00